Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Churchill, D. N.
Right arrow Articles by Taylor, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Churchill, D. N.
Right arrow Articles by Taylor, D. W.

Journal of the American Society of Nephrology, Vol 4, 1809-1813, Copyright © 1994 by American Society of Nephrology

REGULAR ARTICLES

Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin [published erratum appears in J Am Soc Nephrol 1994 Jul;5(1):121]

DN Churchill, N Muirhead, M Goldstein, G Posen, W Fay, ML Beecroft, J Gorman and DW Taylor
St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.

The objective was to evaluate the effect of the treatment of anemia with recombinant human erythropoietin (EPO) on thrombosis of the vascular access used for hemodialysis. The research design was a prospective cohort study comparing EPO-treated hemodialysis patients with a comparison group matched for type of vascular access, clinical center, and age. All patients commencing hemodialysis in the study centers between March 1988 and July 1991 were eligible if either a graft or fistula had been used as a first permanent vascular access. There were 64 matched fistula pairs and 38 matched graft pairs. There were more patients with a history of cardiovascular disease in the EPO group than in the comparison group for both fistulae and grafts, 34 versus 14% for the former and 37 versus 5% for the latter. There was no difference between EPO and comparison groups with respect to time to first thrombosis of fistula, 11.3 versus 10.6%, respectively, by thrombosis of grafts among those treated with EPO--33.6 versus 11.2% (P = 0.02). EPO treatment does not increase the probability of fistula thrombosis, but there is an association with an increased probability of graft thrombosis.


This article has been cited by other articles:


Home page
 CJASNHome page
I. Lenga, C. Lok, R. Marticorena, J. Hunter, N. Dacouris, and M. Goldstein
Role of Oral Iron in the Management of Long-Term Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 688 - 693.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Y.-D. Tang and S. D. Katz
Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options
Circulation, May 23, 2006; 113(20): 2454 - 2461.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G.M. Felker, K. F. Adams Jr, W. A. Gattis, and C. M. O'Connor
Anemia as a risk factor and therapeutic target in heart failure
J. Am. Coll. Cardiol., September 1, 2004; 44(5): 959 - 966.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
B. G. Feagan, C. J. Wong, A. Kirkley, D.W.C. Johnston, F. C. Smith, P. Whitsitt, S. L. Wheeler, and C. Y. Lau
Erythropoietin with Iron Supplementation To Prevent Allogeneic Blood Transfusion in Total Hip Joint Arthroplasty: A Randomized, Controlled Trial
Ann Intern Med, December 5, 2000; 133(11): 845 - 854.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
N. IKEGAYA, T. YAMAMOTO, A. TAKESHITA, T. WATANABE, K. YONEMURA, T. MIYAJI, K. OHISHI, M. FURUHASHI, Y. MARUYAMA, and A. HISHIDA
Elevated Erythropoietin Receptor and Transforming Growth Factor-{beta}1 Expression in Stenotic Arteriovenous Fistulae Used for Hemodialysis
J. Am. Soc. Nephrol., May 1, 2000; 11(5): 928 - 935.
[Abstract] [Full Text]

Home page
 J. Am. Soc. Nephrol.Home page
G. METRY, B. WIKSTRÖM, S. VALIND, B. SANDHAGEN, T. LINDE, S. BESHARA, and B. G. DANIELSON
Effect of Normalization of Hematocrit on Brain Circulation and Metabolism in Hemodialysis Patients
J. Am. Soc. Nephrol., April 1, 1999; 10(4): 854 - 863.
[Abstract] [Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673